Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants
NCT07784335Phase 1Not yet recruiting
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Huperzine A Oral Solution with Placebo (2 arms). Primary endpoint: Safety and Tolerability Assessments. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Huperzine A
Beyond the preview
Go deeper on NCT07784335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784335.